Scalable Cell Therapy CDMO Services Built for Your Clinical Journey
At Cellipont Bioservices, we deliver expert-driven cell therapy CDMO services and solutions that empower innovators to bring transformative treatments from concept to clinic across CAR-T, allogeneic, iPSC, and exosome platforms, all supported by a purpose-built cGMP facility and a team of industry veterans. Our services are designed to support the entire lifecycle of cell and gene therapy development, with tailored solutions that ensure safety, efficacy, and regulatory compliance at every stage. By combining deep technical expertise with a collaborative approach, we enable seamless transitions from process development to clinical and commercial manufacturing, making Cellipont your trusted partner for cell therapy success.
Our Cell Therapy Solutions
We offer a comprehensive suite of cell therapy solutions, including:
Additional Cell Therapy Modalities Supported:
- Dendritic Cells (DCs)
- Fibroblasts
- Natural Killer (NK) Cells
- Hematopoietic Stem Cells (HSCs)
- Tumor-Infiltrating Lymphocytes (TILs)
- GMP Cell Banking (MCB, WCB)
- Feeder Cell Banks
End-to-End Cell Therapy CDMO Services
Our end-to-end approach covers every milestone in your cell therapy journey.
Process & Analytical Development
GMP Cell Banking
Clinical & Commercial Manufacturing
Quality Control & Release Testing
Regulatory Support
Process & Analytical Development
GMP Cell Banking
Clinical & Commercial Manufacturing
Quality Control & Release Testing
Regulatory Support
Our Capabilities
Our team's expertise in cell therapy manufacturing ensures your program benefits from best-in-class science, technology, and operational excellence.
GMP & Regulatory Compliance
Cellipont Bioservices is committed to the highest standards of quality and regulatory compliance:
- Adherence to FDA and EMA guidelines for cell and gene therapy CDMO services.
- Robust QA/QC systems, including electronic batch records, real-time monitoring, and comprehensive documentation.
Why Choose Cellipont Bioservices
Choosing the right manufacturing partner is critical for the success of your cell therapy program. Here's why Cellipont stands out:
Specialized Expertise
Decades of experience in cell therapy CDMO services and cell therapy solutions.
Flexible, Client-Centric Approach
Customizable offerings to fit your project’s unique needs, from early research to commercial launch.
Cutting-Edge Technology
Investment in the latest manufacturing platforms and analytical tools.
Transparent Communication
Dedicated project managers and clear, milestone-driven timelines.
Proven Track Record
Successful support of numerous IND and BLA submissions across multiple cell therapy modalities.
What Our Customers Are Saying
"We are excited to collaborate with Cellipont Bioservices, leveraging their expertise in cell therapy manufacturing to carry out our mission of bringing innovative CAR-T cell therapies to patients in need. This new partnership helps enable Wugen to achieve our mission to help patients with hematological malignancies with off-the-shelf cell therapies."
"Cellipont is a strong partner for us and has excellent manufacturing capabilities to support advancing our lead candidate MGB-001 into the clinic. Our TCR-T therapies have the potential to transform the treatment of cancer and with Cellipont’s team of experts on board, we are on target to bring this very promising therapy to patients who have failed approved, front-line therapies in multiple tumor indications."
Our Cell Therapy Manufacturing Facility
Our state-of-the-art manufacturing facility is designed for flexibility, scalability, and compliance:
- Multiple cGMP suites for parallel manufacturing streams.
- Ballroom-style Flex Suite for exosome and large-scale cell therapy production.
- Advanced environmental monitoring and electronic batch record systems.
- Secure, redundant infrastructure for uninterrupted operations.
Ready to take the next step in cell therapy manufacturing?
Connect with Cellipont Bioservices today and discover how our expertise can accelerate your program and deliver life-changing therapies to patients worldwide.
Let’s work togetherFAQs
We design manufacturing processes with lifecycle scalability in mind from the outset. This includes deliberate platform selection (closed or semi-closed systems where possible), early definition of critical quality attributes (CQAs), and robust process characterization to support scale-up and tech transfer. Our team applies risk-based comparability strategies aligned with FDA and EMA expectations to enable smooth transitions across clinical phases and into commercial manufacturing without compromising product quality or regulatory confidence.
Our approach is phase-appropriate and risk-driven. For early-stage programs, we focus on establishing a reproducible, GMP-ready process with fit-for-purpose analytical methods that support IND-enabling activities. As programs mature, we expand process characterization, assay qualification, and control strategies to support later-phase studies and eventual licensure. This ensures manufacturing readiness aligns with both clinical timelines and regulatory expectations, without over-engineering too early.
Cellipont integrates regulatory strategy directly into process and manufacturing execution. Our quality systems, documentation practices, and control strategies are built to support IND, CTA, and BLA submissions across diverse cell therapy modalities, including CAR-T, TCR-T, iPSC-derived products, and exosomes. We provide technical support for regulatory queries, comparability assessments, and CMC sections, helping sponsors confidently address agency feedback throughout development.